ReviewMolecular biology reports2026
Genetic and epigenetic landscape of non-familial sudden cardiac death.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sudden cardiac death (SCD) remains a major global health challenge, characterized by high incidence, low survival rates, and often presenting as the first manifestation of underlying disease. This review provides a comprehensive overview of the genetic and epigenetic landscape of non-familial SCD, emphasizing the multifactorial nature of this complex clinical endpoint. We summarize common single nucleotide polymorphisms and insertion/deletion variants associated with SCD, identified through candidate-gene-based studies and genome-wide association studies, highlighting risk variants clustered in genes involved in cardiovascular function, signal transduction, and cellular metabolism. We also describe the main epigenetic mechanisms - including microRNAs, DNA methylation, and histone modifications - that may contribute to SCD susceptibility and pathogenesis. Tissue-based and circulating microRNAs can act as mechanistic regulators of SCD pathogenesis and have emerged as exploratory biomarker candidates. However, inconsistent directions of association, methodological heterogeneity, and limited independent validation currently preclude their clinical application. DNA methylation studies, though scarce, suggest potential roles for imprinted genes and oxidative stress pathways. Histone modifications and chromatin remodeling represent underexplored but promising areas. We conclude that addressing the missing heritability of SCD and translating these molecular insights into clinical practice will require large-scale, integrative, and multi-ethnic studies combining genomic, epigenomic, and clinical data with functional validation.
Indexed as
Identifiers
42801373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.